Joint Formulary & PAD

Linzagolix - Endometriosis

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Tablets
Associated Icons :
Restrictions / Comments :
Important

The specialist team should initiate treatment and prescribe at least 1 month of linzagolix prior to transfer of care.

PAD Profile

ChemicalSubstance :
Linzagolix
Indication :
Endometriosis
Group Name :
Keywords :
Brand Names Include :
Yselty
Important Information :
Latest Additions Date From :
03 Sep 2025
Latest Additions Date To :
Guidelines :
Supporting Documents :
2

Committee Recommendations (1)

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed implementation of linzagolix for treating the symptoms of endometriosis in line with NICE TA1067.

Linzagolix for this indication will be considered as BLUE (following specialist team initiation) on the traffic light system. Specialist will be expected to prescribe a minimum of 1 month of linzagolix before requesting transfer of care to the primary care prescriber.

A DXA scan is recommended after the first 52 weeks of treatment to verify that the patient does not have an unwanted degree of BMD loss, that exceeds the benefit of treatment. This DXA scan will be organised & performed by the specialist team responsible for the ongoing care of the patient

Other Indications

Below are listed other indications that Linzagolix is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Endometriosis.